Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has become a promising investment opportunity in the biopharmaceutical industry. Bloomberg reports that 14 research firms are currently covering the firm and have given an average recommendation of “Moderate Buy” for its shares. This is a testament to Apellis’ dedication to discovering, developing and commercializing novel therapeutic compounds to address diseases with high unmet needs.
The founders of Apellis Pharmaceuticals, Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels founded the company on September 25, 2009. The company is headquartered in Waltham, Massachusetts. Over the past decade, the team has worked tirelessly to establish itself as a leader in biopharmaceutical innovation.
With three investment analysts rating the stock as a hold rating, five analysts giving a buy rating and one issuing a strong buy rating on the company’s stock – Apellis Pharmaceuticals appears as an attractive investment option. Notably, the average 12-month price objective among brokerages who have issued ratings on Apellis’ stock over the last year was $90.93.
Currently, institutional investors and hedge funds continue to invest in Apellis’ shares – adding more credibility to what many believe will become one of America’s leading biopharmaceutical companies. Renaissance Technologies LLC bought a new stake in Apellis Pharmaceuticals during the third quarter valued at $23.57 million dollars.
Similarly, Lord Abbett & CO., LLC invested $64.65 million dollars worth of Apellis Pharmaceuticals’ shares during the third quarter while Nuveen Asset Management LLC raised its stake by 9.1%. Putnam Investments LLC also bought several shares worth approximately $7.22 million dollars while Macquarie Group Ltd raised its holdings by 2.7%. All these investments point to growing confidence among investors concerning Apellis Pharmaceuticals’ outlook.
In conclusion, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a biopharmaceutical company with a solid foundation and an unwavering commitment to providing novel therapeutic compounds for diseases with high unmet needs. Its growth prospects and investor confidence in the company have created a promising investment opportunity for those looking to diversify their portfolio. Only time will tell how well Apellis Pharmaceuticals will do in the industry, but early signs show that it is moving in the right direction, which gives the market many reasons for optimism.
Apellis Pharmaceuticals Receives Target Price Boosts from Equities Analysts, Despite Insider Selling and Negative Metrics
Apellis Pharmaceuticals, Inc. is a biopharmaceutical enterprise that has made great strides in the discovery, development, and commercialization of therapeutic compounds. The firm primarily focuses on treating diseases with high unmet needs. Its shareholders and investors have recently received encouraging news pertaining to the boost in target prices by some of the most respected equities analysts.
Bank of America has increased Apellis Pharmaceuticals’ target price from $112 to $114 in a research note published on May 5th, whereas Wedbush has raised the company’s target price from $51 to $67 while giving it a “neutral” rating. HC Wainwright has also boosted its price objective from $87 to $100, whereas Citigroup has upped its price target on Apellis Pharmaceuticals from $88 to $106 in another research note released recently.
Finally, Raymond James, one of the leading financial institutions in the world, gave the company a “strong-buy” rating after increasing the firm’s target price from $123 to $139 on February 22nd earlier this year. It is worth noting that this unexpected development could change investors’ perceptions regarding Apellis Pharmaceuticals’ growth potential & long-term outlook significantly.
Apart from this recent good news for investors, there were also some insider trading activities involving top management executives at Apellis Pharmaceuticals. CEO Cedric Francois sold 30,000 shares of company stock in an SEC filing dated May 16th for a total value of more than $2.5 million.
Following the sale transaction disclosed with SEC policymakers, he still owned about 274,655 shares valued at over 23 million dollars. Pascal Deschatelets also sold 12k shares of company stock in a transaction which took place back on March 8th earlier this year and following this sale he now owns over one million shares which are valued at over sixty-five million dollars.
In any case, these insider activities, have not impacted the market capitalization of Apellis Pharmaceuticals, which currently stands at over $9.92 billion, and the company’s stock price opened for trading last week at $85.15 on Friday. It is an increment from its 52-week low of about $37.66 to the 52-week high of approximately $94.45 in recent months.
Despite reporting ($1.56) EPS and having a revenue of approximately $44.8 million in its last quarterly earnings report that fell short of analysts’ forecasts; attention should be paid to Apellis Pharmaceuticals’ progress in returning consistent results in the face of negativity.
The firm has had a negative return on equity of around 225.82% and negative net margin profits amounting to -652.50%. However, there seems to be hope as its revenue surged by as much as 211%, compared to the same time last year when it posted -1.42 earnings per share (EPS).
While Apellis Pharmaceuticals is yet to turn a profit, financial forecasters hold bullish sentiments towards its future potential with sell-side analysts predicting that the enterprise will post -5.22 EPS for the current fiscal year.
In conclusion, while insiders have been selling off shares of Apellis Pharmaceutical in recent times, along with reports showing less than desirable performances by some metrics like earning per share (EPS), investors should remain focused on information regarding their development pipeline and consistency achieving positive results which depict long-term growth potential for this biopharmaceutical innovative enterprise located in Waltham Massachusetts.hieveing
Discussion about this post